The BETACONNECT™ system: MS therapy goes digital

Abstract

Adherence to long-term treatment in chronic diseases such as multiple sclerosis is challenging. Many disease-modifying drugs (DMDs) for MS need to be injected. Injection devices may improve satisfaction with the injection procedure and boost adherence. Meeting patients' needs in handling and design of autoinjectors and other supporting elements may be key to successful therapy. The BETACONNECT™ system is a platform-based approach in DMD therapy. It combines autoinjector technology with digital tools to support patient self-management and facilitate communication between patients and healthcare providers. Here, we describe the components of the BETACONNECT system and review data on patients' satisfaction with the BETACONNECT autoinjector and how it compares to other devices. Additionally, we present first data on patients' satisfaction with the myBETAapp™.

Keywords: BETACONNECT™; IFN-β 1b; adherence; autoinjector; data sharing; disease-modifying drug therapy; multiple sclerosis; myBETAapp™; satisfaction.